A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients, which is having a profound negative impact on patient care.1,2

Novartis is prioritizing patients who have received at least one dose and are currently in treatment, followed by those who are in the scheduling system awaiting their first dose. The company has stated that it will not accept new patient starts until the Millburn, NJ, manufacturing site is approved by the FDA, which they project will take 4 to 6 months.

Why It’s Important

The FDA approved Pluvicto in March 2022 to treat metastatic castration-resistant prostate cancer. The therapy was shown to significantly improve overall survival.
Currently, only one site (Novartis facility in Ivrea, Italy) is approved by the FDA to manufacture 177Lu-PSMA-617 for commercial use. Each small batch made has only a 5-day window to reach the intended patient; any disruption in the production or shipping process can create a delay. If that delay extends beyond the 5-day window, the dose must be destroyed and the patient rescheduled, which then has ripple effects through the waiting list and patient treatment schedule.

What SNMMI Is Doing

SNMMI is pursuing several pathways to help resolve this crisis, including:

  • Sending a letter to the FDA this week about potential options, including expedited review for the Millburn, NJ, manufacturing site.
  • Further discussing the situation with Novartis leadership, who are creatively investigating all options.
  • Working with patient groups to enlist their assistance in petitioning the FDA regarding the drug shortage and to ensure the patient voice is being heard.
  • Discussing other potential options to help alleviate the shortage with the nuclear medicine community.

What’s Next

SNMMI will continue discussions with Novartis and the FDA to propose other potential options to help alleviate the shortage.

Novartis’s manufacturing site in Millburn, NJ, can produce Pluvicto for use with research patients and has applied for expedited FDA review for commercial production; if approved, the review would take 4-6 months. In addition, Novartis is building a new manufacturing facility for Pluvicto in Indianapolis, which they expect will be operational by the end of 2023.

Several new compounds are in phase 3 clinical trials, including, for example, SPLASH (NCT0464752, POINT Biopharma/Lantheus) and ECLIPSE (NCT05204927, Curium). It is possible that enrollment in clinical trials may be the only way that new patients who have metastatic prostate cancer and are eligible for Pluvicto may receive PSMA-targeted radiopharmaceutical therapy in the U.S. Similar treatments may be available outside of the U.S.

SNMMI is very concerned about this situation and will work vigorously to help make lifesaving/life-prolonging radiopharmaceutical therapies available to patients in need.

For more information: www.snmmi.org

References:

1.    Ravi P, Whelpley B, Kelly E, et al. Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges. J Nucl Med. 2023 Mar;64(3):349-350. DOI: https://doi.org/10.2967/jnumed.122.265194

2.    Czernin J, Calais J. The 177Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. J Nucl Med. 2023 Mar;64(3):343. DOI: https://doi.org/10.2967/jnumed.123.265459

Related Medical Radioisotopes Content:

University of Missouri Research Reactor Helps Supply Critical Medical Isotopes During Global Disruption

Update on Unplanned Outage of the HFR Reactor

SNMMI Issues Alert That HFR Outage Will Impact Isotope Supply

NorthStar Medical Radioisotopes Advances Focus on Therapeutic and Specialized SPECT Radiopharmaceuticals

How Nuclear Fusion is Revolutionizing Medical Isotope Production

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes

Medical Isotope Industry Opposes Export of Highly Enriched Uranium for IRE

IBA and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Tc-99m

VIDEO: Advances in Radiopharmaceutical Therapy


Related Content

News | Digital Pathology

March 21, 2023 — Pramana, Inc., an AI-enabled health tech company modernizing the pathology sector, and PathPresenter ...

Time March 21, 2023
arrow
News | PET-CT

March 21, 2023 — Positron Corporation, a molecular imaging device company that offers PET imaging systems and clinical ...

Time March 21, 2023
arrow
News | Radiology Business

March 21, 2023 — Boston Imaging, a subsidiary of Samsung Electronics, Co. Ltd, appoints Eric Sumner as the new Digital ...

Time March 21, 2023
arrow
News | Digital Radiography (DR)

March 20, 2023 — A study by Emory Healthcare reports that Konica Minolta Healthcare’s Dynamic Digital Radiography (DDR) ...

Time March 20, 2023
arrow
News | Radiopharmaceuticals and Tracers

March 20, 2023 — RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against ...

Time March 20, 2023
arrow
News | X-Ray

March 20, 2023 — Researchers from UNSW Sydney have developed an algorithm which produces high-resolution modeled images ...

Time March 20, 2023
arrow
Feature | Magnetic Resonance Imaging (MRI) | By Brad Sutton

March 16, 2023, marks 50 years since Paul Lauterbur published his seminal Nature paper establishing zeugmatography — now ...

Time March 16, 2023
arrow
News | Coronavirus (COVID-19)

March 13, 2023 — The American College of Radiology (ACR) and the American College of Emergency Physicians (ACEP) ...

Time March 13, 2023
arrow
Videos | Enterprise Imaging

Philips Radiology Operations Command Center (ROCC) is a vendor-neutral, multi-modality, multi-site telepresence tool ...

Time March 13, 2023
arrow
News | Contrast Media

March 9, 2023 — Contrast agents used in MRI scans to improve the clarity of imaging for diagnostic accuracy, accumulate ...

Time March 09, 2023
arrow
Subscribe Now